Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -323,986 | -356,422 | -281,310 | -282,089 | -159,429 |
| Depreciation Amortization | 102,834 | 108,639 | 21,192 | 19,553 | 272 |
| Accounts receivable | -16,338 | -7,990 | -1,519 | -1,736 | 27,000 |
| Accounts payable and accrued liabilities | 6,900 | -5,448 | -1,824 | 4,425 | -360 |
| Other Working Capital | -43,882 | 665 | -4,774 | 39,972 | 34,272 |
| Other Operating Activity | 57,897 | 67,008 | 46,697 | 41,373 | -7,916 |
| Operating Cash Flow | $-216,575 | $-193,548 | $-221,538 | $-178,502 | $-106,161 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -6,886 | -3,210 | -10,375 | -4,098 | -3,230 |
| Net Acquisitions | N/A | N/A | N/A | -818 | N/A |
| Purchase Of Investment | -263,923 | -347,966 | -183,590 | -259,304 | -331,362 |
| Sale Of Investment | 385,432 | 232,178 | 172,000 | 276,469 | 317,000 |
| Purchase Sale Intangibles | N/A | N/A | N/A | -118 | 0 |
| Other Investing Activity | -4,883 | -19,800 | -7,700 | -118 | 0 |
| Investing Cash Flow | $109,740 | $-138,798 | $-29,665 | $12,131 | $-17,592 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 48,415 | 98,150 | N/A | 287,500 | N/A |
| Debt Repayment | -18,255 | -11,097 | N/A | N/A | N/A |
| Common Stock Issued | 115,472 | 252,834 | 38,394 | 90,840 | 223,777 |
| Other Financing Activity | -9,065 | -8,193 | -8,525 | -46,856 | -2,120 |
| Financing Cash Flow | $136,567 | $331,694 | $29,869 | $331,484 | $221,657 |
| Beginning Cash Position | 115,017 | 115,669 | 337,003 | 171,890 | 73,986 |
| End Cash Position | 144,749 | 115,017 | 115,669 | 337,003 | 171,890 |
| Net Cash Flow | $29,732 | $-652 | $-221,334 | $165,113 | $97,904 |
| Free Cash Flow | |||||
| Operating Cash Flow | -216,575 | -193,548 | -221,538 | -178,502 | -106,161 |
| Capital Expenditure | -6,886 | -3,210 | -10,375 | -4,098 | -3,230 |
| Free Cash Flow | -223,461 | -196,758 | -231,913 | -182,600 | -109,391 |